These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23819776)

  • 1. Statin diabetogenicity: guidance for clinicians.
    Ray K
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S3. PubMed ID: 23819776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins in cardiometabolic disease: what makes pitavastatin different?
    Ginsberg H
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S1. PubMed ID: 23819727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitavastatin in cardiometabolic disease: therapeutic profile.
    Masana L
    Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S2. PubMed ID: 23819752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice.
    Sattar NA; Ginsberg H; Ray K; Chapman MJ; Arca M; Averna M; Betteridge DJ; Bhatnagar D; Bilianou E; Carmena R; Ceška R; Corsini A; Erbel R; Flynn PD; Garcia-Moll X; Gumprecht J; Ishibashi S; Jambart S; Kastelein JJ; Maher V; da Silva PM; Masana L; Odawara M; Pedersen TR; Rotella CM; Salti I; Teramoto T; Tokgozoglu L; Toth PP; Valensi P; Vergès B
    Atheroscler Suppl; 2014 Jun; 15(1):1-15. PubMed ID: 24840509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial.
    Park JB; Jung JH; Yoon YE; Kim HL; Lee SP; Kim HK; Kim YJ; Cho GY; Sohn DW
    Trials; 2017 Oct; 18(1):501. PubMed ID: 29078817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetogenic Action of Statins: Mechanisms.
    Carmena R; Betteridge DJ
    Curr Atheroscler Rep; 2019 Apr; 21(6):23. PubMed ID: 31037345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitavastatin: clinical effects from the LIVES Study.
    Teramoto T
    Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS).
    Zhang J; Shao Y; Liu Y; Tao J
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):581-589. PubMed ID: 30187345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes Secondary to Treatment with Statins.
    Laakso M; Kuusisto J
    Curr Diab Rep; 2017 Feb; 17(2):10. PubMed ID: 28155189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atherogenic dyslipidemia increases the risk of incident diabetes in statin-treated patients with impaired fasting glucose or obesity.
    Barkas F; Elisaf M; Liberopoulos E; Liamis G; Ntzani EE; Rizos EC
    J Cardiol; 2019 Sep; 74(3):290-295. PubMed ID: 30910387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin use and risk for type 2 diabetes: what clinicians should know.
    Maki KC; Diwadkar-Navsariwala V; Kramer MW
    Postgrad Med; 2018 Mar; 130(2):166-172. PubMed ID: 29139315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low-Risk Population With Type 2 Diabetes Mellitus.
    Malmborg M; Schmiegelow MDS; Gerds T; Schou M; Kistorp C; Torp-Pedersen C; Gislason G
    J Am Heart Assoc; 2021 Jul; 10(13):e020395. PubMed ID: 34151606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
    Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
    Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
    Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pitavastatin and new diabetes development].
    Beyaz Ş; Ükinç K
    Turk Kardiyol Dern Ars; 2017 Apr; 45(Suppl 3):13-15. PubMed ID: 28952473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA; Davis K
    Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.